SCZD6
MCID: SCH081
MIFTS: 27

Schizophrenia 6 (SCZD6)

Categories: Genetic diseases, Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Schizophrenia 6

MalaCards integrated aliases for Schizophrenia 6:

Name: Schizophrenia 6 57 12 29 72
Schizophrenia Susceptibility Locus, Chromosome 8p-Related 57 13
Sczd6 57 12
Schizophrenia, Type 6 40

Classifications:



External Ids:

Disease Ontology 12 DOID:0070082
OMIM 57 603013
MedGen 42 C1864275
UMLS 72 C1864275

Summaries for Schizophrenia 6

Disease Ontology : 12 A schizophrenia that has material basis in an autosomal dominant mutation of SCZD6 on chromosome 8p21.

MalaCards based summary : Schizophrenia 6, also known as schizophrenia susceptibility locus, chromosome 8p-related, is related to schizophrenia and myocardial infarction. An important gene associated with Schizophrenia 6 is NRG1 (Neuregulin 1). The drugs Tranquilizing Agents and Antidepressive Agents have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and testes.

More information from OMIM: 603013

Related Diseases for Schizophrenia 6

Symptoms & Phenotypes for Schizophrenia 6

Clinical features from OMIM:

603013

Drugs & Therapeutics for Schizophrenia 6

Drugs for Schizophrenia 6 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 32)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Tranquilizing Agents Phase 3
2 Antidepressive Agents Phase 3
3 Quetiapine Fumarate Phase 3 111974-72-2
4 Central Nervous System Depressants Phase 3
5 Antipsychotic Agents Phase 3
6 Psychotropic Drugs Phase 3
7
Oxytocin Approved, Vet_approved Phase 2 50-56-6 439302 53477758
8
Olanzapine Approved, Investigational Phase 2 132539-06-1 4585
9
Rimonabant Approved, Investigational Phase 2 158681-13-1, 168273-06-1 104850
10
Serine Approved, Nutraceutical Phase 2 56-45-1 5951
11 Oxytocics Phase 2
12 Serotonin Agents Phase 2
13 Serotonin Uptake Inhibitors Phase 2
14 Antiemetics Phase 2
15 Gastrointestinal Agents Phase 2
16 Peripheral Nervous System Agents Phase 2
17 Neurotransmitter Uptake Inhibitors Phase 2
18 Autonomic Agents Phase 2
19 Neurotransmitter Agents Phase 2
20 Hormone Antagonists Phase 2
21 Hormones Phase 2
22 Anti-Obesity Agents Phase 2
23 Cannabinoid Receptor Antagonists Phase 2
24 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
25
Serotonin Investigational, Nutraceutical Phase 2 50-67-9 5202
26
Dopamine Approved 51-61-6, 62-31-7 681
27 Dopamine Agents
28 Serotonin 5-HT2 Receptor Antagonists
29 Serotonin Antagonists
30 Paliperidone Palmitate
31 Dopamine Antagonists
32 Dopamine D2 Receptor Antagonists

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 6-week Multicenter, Double-blind, Randomized, Parallel-group, Phase 3 Study to Evaluate the Feasibility of Switching From Immediate-release Quetiapine Fumarate (SEROQUEL) to Sustained-release Quetiapine Fumarate in Outpatients With Schizophrenia (Abbreviated) Completed NCT00206128 Phase 3 Seroquel SR
2 A Randomized Trial Administering Oxytocin vs Placebo as add-on to Antipsychotics in Patients With Schizophrenia and Schizo-affective Disorder Unknown status NCT01598623 Phase 2 Oxytocin
3 D-serine Antipsychotic Monotherapy for Treatment Refractory Schizophrenia Completed NCT00816894 Phase 2 D-serine;Olanzapine
4 The Effects of the Cannabinoid-1 Receptor Antagonist, Rimonabant, on Weight and Metabolic Risk Factors in People With Schizophrenia Terminated NCT00547118 Phase 2 Rimonabant;Placebo
5 Expanding Rapid Ascertainment Networks of Schizophrenia Families in Taiwan Unknown status NCT01357005
6 Expanding Rapid Ascertainment Network of Schizophrenia Families in Taiwan Unknown status NCT01249079
7 Expanding Rapid Ascertainment Networks of Schizophrenia Families in Taiwan Unknown status NCT01077687
8 INVega Is Studied In an Observational Design in the Netherlands Completed NCT00697658 Paliperidone ER
9 The Effectiveness of The Meta-cognitive Training Among Chronic Schizophrenia Patients Treated Within Community Support Groups in Poland. Completed NCT02187692
10 Cognitive Remediation Program for Hospitalized in the Long Term Patients With Deficit Schizophrenia : Impact on the Capacities of Autonomy Not yet recruiting NCT03407950

Search NIH Clinical Center for Schizophrenia 6

Genetic Tests for Schizophrenia 6

Genetic tests related to Schizophrenia 6:

# Genetic test Affiliating Genes
1 Schizophrenia 6 29 NRG1

Anatomical Context for Schizophrenia 6

MalaCards organs/tissues related to Schizophrenia 6:

41
Brain, Cortex, Testes, Prefrontal Cortex

Publications for Schizophrenia 6

Articles related to Schizophrenia 6:

(show top 50) (show all 52)
# Title Authors PMID Year
1
Extreme population differences across Neuregulin 1 gene, with implications for association studies. 8
16189508 2006
2
No evidence for linkage or association of neuregulin-1 (NRG1) with disease in the Irish study of high-density schizophrenia families (ISHDSF). 8
15197397 2004
3
Identification of a novel neuregulin 1 at-risk haplotype in Han schizophrenia Chinese patients, but no association with the Icelandic/Scottish risk haplotype. 8
15007393 2004
4
No association with the neuregulin 1 haplotype to Japanese schizophrenia. 8
14699424 2004
5
Polymorphisms within 5' end of the Neuregulin 1 gene are genetically associated with schizophrenia in the Chinese population. 8
14647391 2004
6
Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia. 8
12851457 2003
7
Evidence for association of schizophrenia with genetic variation in the 8p21.3 gene, PPP3CC, encoding the calcineurin gamma subunit. 8
12851458 2003
8
Neuregulin 1 and susceptibility to schizophrenia. 8
12145742 2002
9
Genetic association studies of schizophrenia using the 8p21-22 genes: prepronociceptin (PNOC), neuronal nicotinic cholinergic receptor alpha polypeptide 2 (CHRNA2) and arylamine N-acetyltransferase 1 (NAT1). 8
11436130 2001
10
Schizophrenia susceptibility loci on chromosomes 13q32 and 8p21. 8
9731535 1998
11
NIMH Genetics Initiative Millenium Schizophrenia Consortium: linkage analysis of African-American pedigrees. 8
9674972 1998
12
Evidence for a schizophrenia vulnerability locus on chromosome 8p in the Irish Study of High-Density Schizophrenia Families. 8
8942448 1996
13
The Johns Hopkins University Collaborative Schizophrenia Study: an epidemiologic-genetic approach to test the heterogeneity hypothesis and identify schizophrenia susceptibility genes. 8
9246505 1996
14
Clinical staging in severe mental disorders; bipolar disorder, depression and schizophrenia. 38
30314812 2019
15
Schizophrenia is a later-onset feature of PCDH19 Girls Clustering Epilepsy. 38
30828795 2019
16
A randomized controlled trial of a mindfulness-based intervention program for people with schizophrenia: 6-month follow-up. 38
27994466 2016
17
Monitoring of physical health parameters for inpatients on a child and adolescent mental health unit receiving regular antipsychotic therapy. 38
26734455 2015
18
Trajectories of antipsychotic response in drug-naive schizophrenia patients: results from the 6-month ESPASS follow-up study. 38
23600715 2014
19
A modified Drug Attitude Inventory used in long-term patients in sheltered housing. 38
23265955 2013
20
Burden of disease in adolescents and young people in Spain. 38
23084798 2013
21
Early-onset schizophrenia. 38
22797279 2012
22
Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. 38
20702068 2011
23
MMPI-II personality profiles of patients with psychogenic nonepileptic seizures. 38
21450531 2011
24
Follow-up of subjects with suspected pre-psychotic state in Taiwan. 38
21112187 2011
25
[Clinical-genetic parameters and the nosological evaluation of schizoaffective psychosis in systematics of attack-like endogenous psychoses]. 38
21512496 2011
26
Diffusion tensor anisotropy in the cingulate gyrus in schizophrenia. 38
20045072 2010
27
Increased risk of acute myocardial infarction after acute episode of schizophrenia: 6 year follow-up study. 38
20050720 2010
28
Increased cortical inhibition in persons with schizophrenia treated with clozapine. 38
18308816 2008
29
GABAA/Benzodiazepine receptor binding in patients with schizophrenia using [11C]Ro15-4513, a radioligand with relatively high affinity for alpha5 subunit. 38
18042347 2008
30
Urticaria and angio-oedema due to ziprasidone. 38
17446198 2007
31
Neurocognitive enhancement therapy with work therapy in schizophrenia: 6-month follow-up of neuropsychological performance. 38
17943687 2007
32
Dysfunction of dorsolateral prefrontal cortex in antipsychotic-naïve schizophreniform psychosis. 38
17052898 2006
33
Association of DISC1/TRAX haplotypes with schizophrenia, reduced prefrontal gray matter, and impaired short- and long-term memory. 38
16275808 2005
34
Hypermetabolic pattern in frontal cortex and other brain regions in unmedicated schizophrenia patients. Results from a FDG-PET study. 38
15834758 2005
35
Longitudinal course of schizophrenia spectrum symptoms in offspring of psychiatrically hospitalized mothers. 38
16092904 2005
36
Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study. 38
15701107 2005
37
[Distribution of latencies of visual evoked potentials in a sample of schizophrenic patients]. 38
14727371 2003
38
A cluster-analytic investigation of MMPI profiles of serious male and female juvenile offenders. 38
12819436 2003
39
Mental illness and menopause: a patient and family perspective. 38
12814000 2003
40
Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia. 38
11317227 2001
41
[Morphometric study of ultrastructural changes in oligodendroglial cells in the postmortem brain in endogenous psychoses]. 38
11523429 2001
42
The carbohydrate deposits detected by histochemical methods in the molecular layer of the dentate gyrus in the hippocampal formation of patients with schizophrenia, Down's syndrome and dementia, and aged person. 38
11443283 2000
43
Adverse behavioral events reported in patients taking alprazolam and other benzodiazepines. 38
8262890 1993
44
Auditory P300 studies in schizophrenic subjects and their first degree relatives. 38
1642573 1992
45
[Review of the concept of personality deterioration in schizophrenia]. 38
1862715 1991
46
[Suicidal tendencies in endogenous and organic depression in elderly patients]. 38
3232462 1988
47
Sialic acid in platelets of schizophrenic patients. 38
3363163 1988
48
Drug-induced growth hormone and prolactin responses in schizophrenia research. 38
6131495 1982
49
Efficacy of loxapine in the treatment of paranoid schizophrenia. 38
14350 1977
50
[Clinico-epidemiologic study of the mental state of a group of elderly persons from the general population]. 38
919967 1977

Variations for Schizophrenia 6

Expression for Schizophrenia 6

Search GEO for disease gene expression data for Schizophrenia 6.

Pathways for Schizophrenia 6

GO Terms for Schizophrenia 6

Sources for Schizophrenia 6

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....